New Data Reveals Elanco's Canine Parvovirus Monoclonal Antibody Treatment Significantly Improves Puppy Survival Rates and Relieves Operational Stress in Veterinary Clinics

Barchart · 10/15 07:27

In the first year, Canine Parvovirus Monoclonal Antibody saved thousands of puppies

GREENFIELD, Ind., Oct. 15, 2024 /PRNewswire/ -- Elanco Animal Health today unleashed the first ever real-world data demonstrating the efficacy and impact of its Canine Parvovirus Monoclonal Antibody (CPMA), the first and only USDA Conditionally Approved targeted treatment for canine parvovirus. Annually, canine parvovirus affects more than 330,000 puppies, contributing up to a staggering 91% mortality rate without supportive care.1, 2 The real-world data, collected over the first year of CPMA availability, shows improvements in survival rates for puppies battling the deadly virus as well as enhanced operational efficiency and high satisfaction within veterinary clinics – serving as a proof point that the Canine Parvovirus Monoclonal Antibody is re-writing the protocol for parvovirus treatment.

Read more at prnewswire.com